LAMA-84（人急變期慢性粒細(xì)胞白血?。?/h1>
CBP61153
詢 價(jià)
索取STR
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫(kù)
| I. General information | |
| Synonyms: | LAMA-84 |
| Background: | established from the peripheral blood of a 29-year-old woman with chronic myeloid leukemia (CML) (treated 5 years with busulfan from 1979-1984) one month after onset of myeloid-megakaryocytic blast crisis; cells were described in the literature to express megakaryocytic and erythroid markers and to respond to induction of differentiation with various reagents; parental cell line of subclone LAMA-87 (DSM ACC 270); cells carry t(9;22) leading to BCR-ABL1 e14-a2 (b3-a2) fusion gene |
| Species: | human (Homo sapiens) |
| Tissue: | N/A |
| Disease: | chronic myeloid leukemia in blast crisis |
| Gender: | N/A |
| Morphology: | single, round to polymorph cells growing in suspension, some cells are loosely adherent with a spindle-like morphology; |
| Growth Mode: | N/A |
| Doubling Time: | ca. 50 hours |
| DNA Profile: | N/A Our Cell Line Authentication Service |
| Culture Medium: |
RPMI-1640+20%FBS LAMA-84完全培養(yǎng)基，# CBP61153M |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Mycoplasma: | negative in DAPI, microbiological culture, RNA hybridization, PCR assays |
| Immunology: | CD3 -, CD11b +, CD13 +, CD15 -, CD19 -, CD33 +; |
| Fingerprint: | unique DNA profile using multiplex PCR at D1S80, D2S44, D17S5 and ApoB |
| Species: | confirmed as human with IEF of AST, MDH |
| Cytogenetics: | human hypertriploid karyotype with 3.6% polyploidy - 73/74(69-77)<3n>XX, -X, +1, -2, +5, +6, +8, +13, -14, +17, +17, -18, +22, +mar, del(7)(p15), der(9)t(9;22)(q34;q11)x2, i(11q), add(13)(q33), del(17)(p12), der(22)t(9;22)(q34;q11)x4 - carries Ph (4 copies) - resembles published karyotype |
| Molec. Genetics: | expression of fusion gene BCR-ABL1 e14-a2 (b3-a2) confirmed by RT-PCR |
| Virus | ELISA: reverse transcriptase negative; PCR: EBV -, HBV -, HCV -, HHV-8 -, HIV-1 -, HIV-2 -, HTLV-I/II -, MLV -, SMRV - |
| Comments: | For more information, please contact us (4008-750-250). |
